A $30 million alliance between Biogen Idec and Columbia University Medical Center was formed to conduct research in genetics and to understand the underlying causes of several diseases such as amyotrophic lateral sclerosis (ALS). This new partnership may help identify new treatment approaches to address the largely unmet clinical needs…
A group of researchers from the King’s College London recently published a new editorial entitled, “Heritability of Amyotrophic Lateral Sclerosis” in the journal JAMA Neurology – the official journal of the American Medical Association, that comments on the heritability estimation results of amyotrophic lateral sclerosis from a previous…
The U.S. Patent and Trademark Office (USPTO) recently granted clinical stage biopharmaceutical company and subsidiary of Allied Minds, SciFluor Life Sciences, LLC, a patent for one of their novel pipeline compounds, SF0034, a potent and selective neuronal potassium channel activator that is being studied for the treatment of epilepsy, amyotrophic lateral sclerosis…
BrainStorm Cell Therapeutics, Inc., a biotechnology company focused on developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), recently announced the latest Phase 2a clinical trial results of NurOwn™, a technology that differentiates bone marrow-derived mesenchymal…
Recent evidence shows that in amyotrophic lateral sclerosis (ALS), there occurs a notable deposition of abnormal ubiquitinated inclusions immunoreactive to TDP-43. In order to provide an early diagnosis and to conduct clinical trials for early treatment for ALS, it is crucial to fully understand muscle pathology in this condition. The study, entitled,…
A recent review, entitled, “Patient-Perceived Outcomes and Quality of Life in ALS”, which was published in the journal Neurotherapeutics last December 11, 2014, examined current evidence concerning the Quality of Life assessment measures for patients with amyotrophic lateral sclerosis (ALS). The…
In trying to determine the basis for volumetric changes seen in patients with amyotrophic lateral sclerosis (ALS), Drs. Venkateswaran Rajagopalan and Erik Pioro of the Cleveland Clinic have used voxel based morphometry to measure motor and extramotor grey matter volumes. The two recently delved into a study,…
The accumulation of specific metals may trigger neuronal degeneration associated with Amyotrophic lateral sclerosis (ALS), according to a study conducted on residents of the Kii Peninsula in Japan. The study, titled, “Neutron Activation Analysis of Scalp Hair from ALS Patients and Residents in the Kii Peninsula, Japan” was…
A new clinical review entitled “Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?”, conducted by Christopher Donnelly from the Department of Neurology of the Johns Hopkins University and colleagues, explores the current status of Amyotrophic lateral sclerosis (ALS) evidence. The study was published…
Clinical-stage biopharmaceutical company Cytokinetics presented their lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), a novel skeletal muscle activator called tirasemtiv, in an oral presentation and four poster presentations, at the 25th International Symposium on ALS/MND, which took place between December 5 and…
Get regular updates to your inbox.
